Plasma cell leukemia: An evaluation of response to therapy

Noël, Pierre; Kyle, Robert A.

doi:10.1016/0002-9343(87)90942-9

Cited by 158 publications

(131 citation statements)

References 38 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…Because of the low frequency of PCL, most of the data has come from case reports or small series of cases [2,5,9,10]. In almost all the series median age ranged between 53 and 57 years.…”

Section: Discussionmentioning

confidence: 99%

“…Median survival is less than 1 year [4]. The longest survival reported is 28 months [5]. Secondary PCL represents a terminal event for a refractory/relapsed MM and is usually not responsive to any treatment modality.…”

Section: Discussionmentioning

confidence: 99%

“…About 60% PCL are primary and the remaining 40% are secondary, part of the terminal phase of MM, which occurs in about 1% of myelomas [5].…”

Section: Introductionmentioning

confidence: 99%

“…Because of the low frequency of PCL, most of the literature is either as case reports or a few reviews [2,5,9,10]. Here we are reporting cases of PCL diagnosed from 2004 to 2007 at our center with their clinical and laboratory features.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Plasma Cell Leukemia: Case Series From a Tertiary Center with Review of Literature

Naseem

Kaur

Gupta

et al. 2011

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Plasma cell leukemia is an unusual manifestation of multiple myeloma, reported to occur in 2% of newly diagnosed patients. It may either present at the time of diagnosis (primary) or evolve as a late feature in the course of multiple myeloma (secondary). Most clinical signs of myeloma are observed in plasma cell leukemia, although osteolytic lesions and bone pain are less frequent and lymphadenopathy, organomegaly and renal failure are more often present. The immunophenotype of plasma cell leukemia differs typically from that of myeloma by lack of aberrant CD56 expression. An abnormal karyotype is more frequently found in plasma cell leukemia and there is higher incidence of unfavourable cytogenetics. Plasma cell leukemia is an aggressive disease, characterized by a fulminant course and a short survival. We are reporting cases of this rare condition which presented at our center over 3 years along with review of literature.

show abstract

“…Because of the low frequency of PCL, most of the data has come from case reports or small series of cases [2,5,9,10]. In almost all the series median age ranged between 53 and 57 years.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…About 60% PCL are primary and the remaining 40% are secondary, part of the terminal phase of MM, which occurs in about 1% of myelomas [5].…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Plasma Cell Leukemia: Case Series From a Tertiary Center with Review of Literature

Naseem

Kaur

Gupta

et al. 2011

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

show abstract

“…There are two forms of PCL: primary and secondary. The primary form, which occurs in individuals without preceding multiple myeloma, is estimatedto account for 50% to 70% ofPCL (1,3). Most cases of primary PCL involve IgG-and light chain-producing cells, and the involvement of IgM and IgA is less frequent (4).…”

Section: Introductionmentioning

confidence: 99%

Long Term Complete Remission in Primary Plasma Cell Leukemia.

et al. 1995

View full text Add to dashboard Cite

A 76-year-old female was diagnosed as having primary plasma cell leukemia (PCL), based on abundant atypical plasma cells in the circulation and bone marrow, monoclonalk light chain in the serum and urine, the immunophenotypeof the plasma cells and the lack of preceding multiple myeloma. The patient was treated with melphalan and prednisolone (MP), and complete remission (CR) was achieved; this was maintained for 28 months. The duration of CRin this patient appears to be the longest of those reported in well-documented primary PCL patients who have been treated with MPchemotherapy. (Internal Medicine 34: 251-254, 1995)

show abstract

Hematological Malignancies Uncommon Presentations of Plasma Cell Dyscrasias

Baz

Hussein

2012

Textbook of Uncommon Cancer

View full text Add to dashboard Cite

Plasma cell leukemia: An evaluation of response to therapy

Cited by 158 publications

References 38 publications

Plasma Cell Leukemia: Case Series From a Tertiary Center with Review of Literature

Plasma Cell Leukemia: Case Series From a Tertiary Center with Review of Literature

Long Term Complete Remission in Primary Plasma Cell Leukemia.

Hematological Malignancies Uncommon Presentations of Plasma Cell Dyscrasias

Contact Info

Product

Resources

About